Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FB849 |
| Synonyms | |
| Therapy Description |
FB849 inhibits MAP4K1 (HPK1), potentially leading to enhanced T-lymphocyte activation and antitumor activity (Cancer Res (2024) 84 (6_Supplement): 2651, Cancer Res (2024) 84 (6_Supplement): 4029). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FB849 | FB-849|FB 849 | MAP4K1 Inhibitor 8 | FB849 inhibits MAP4K1 (HPK1), potentially leading to enhanced T-lymphocyte activation and antitumor activity (Cancer Res (2024) 84 (6_Supplement): 2651, Cancer Res (2024) 84 (6_Supplement): 4029). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05761223 | Phase Ib/II | FB849 FB849 + Pembrolizumab | A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | Recruiting | USA | 0 |